A key opinion leader discusses the CARD Study and how the emerging data has impacted the treatment of prostate cancer.
EP. 1: Counseling Patients About Therapy Selection
EP. 2: CARD Study: Pain Response and Quality of Life Analysis
EP. 3: CARD Trial Regimen After AR-Targeted or Chemotherapy
EP. 4: Advanced Disease: AR-Targeted or Chemotherapy?
EP. 5: AR-Targeted Therapy MORE and Cross Resistance
EP. 6: The Future of Advanced Prostate Cancer Management
FDA grants breakthrough device designation for ArteraAI Prostate tool
Data supports combination intravesical chemotherapy for high-risk NMIBC
EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC
FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC